Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERMNASDAQ:ENTANASDAQ:NXTCNASDAQ:ODTNASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$7.10+0.9%$7.03$3.54▼$8.25$165.40M0.889,734 shs84,240 shsENTAEnanta Pharmaceuticals$7.89-1.0%$6.54$4.09▼$17.24$168.66M0.84283,659 shs78,004 shsNXTCNextCure$0.44+2.0%$0.48$0.22▼$1.82$12.22M1.06127,114 shs86,057 shsODTOdonate Therapeutics$1.27$0.85▼$7.10N/AN/AN/A87,682 shsSUPNSupernus Pharmaceuticals$32.00-0.2%$32.26$25.94▼$40.28$1.79B0.7478,210 shs212,566 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical0.00%-0.56%-5.84%-1.25%+37.86%ENTAEnanta Pharmaceuticals0.00%+5.20%+9.43%+66.81%-39.95%NXTCNextCure0.00%-2.89%-11.81%+12.02%-72.17%ODTOdonate Therapeutics0.00%0.00%0.00%0.00%0.00%SUPNSupernus Pharmaceuticals0.00%+2.68%-1.07%-2.28%+23.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDERMJourney Medical1.6575 of 5 stars3.51.00.00.00.61.70.6ENTAEnanta Pharmaceuticals4.0828 of 5 stars3.42.00.04.72.42.50.0NXTCNextCure4.129 of 5 stars3.53.00.04.30.01.71.3ODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASUPNSupernus Pharmaceuticals2.828 of 5 stars2.22.00.04.13.20.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 3.00Buy$9.5033.80% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$18.00128.14% UpsideNXTCNextCure 3.00Buy$3.50700.92% UpsideODTOdonate Therapeutics 0.00N/AN/AN/ASUPNSupernus Pharmaceuticals 2.33Hold$36.0012.52% UpsideCurrent Analyst Ratings BreakdownLatest ENTA, ODT, DERM, NXTC, and SUPN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.006/3/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.005/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$56.13M2.95N/AN/A$0.91 per share7.80ENTAEnanta Pharmaceuticals$67.64M2.49N/AN/A$6.08 per share1.30NXTCNextCureN/AN/AN/AN/A$2.34 per shareN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/ASUPNSupernus Pharmaceuticals$661.82M2.71$4.17 per share7.67$18.76 per share1.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)NXTCNextCure-$55.65M-$1.76N/AN/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)ODTOdonate Therapeutics-$126.35MN/A0.00N/AN/AN/AN/AN/AN/ASUPNSupernus Pharmaceuticals$73.86M$1.1128.8222.22N/A9.27%12.23%9.17%8/5/2025 (Estimated)Latest ENTA, ODT, DERM, NXTC, and SUPN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical1.071.341.03ENTAEnanta PharmaceuticalsN/A5.295.29NXTCNextCureN/A10.2610.26ODTOdonate TherapeuticsN/AN/AN/ASUPNSupernus PharmaceuticalsN/A2.442.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%ENTAEnanta Pharmaceuticals94.99%NXTCNextCure42.65%ODTOdonate TherapeuticsN/ASUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%ENTAEnanta Pharmaceuticals13.89%NXTCNextCure17.90%ODTOdonate Therapeutics48.90%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9023.30 million19.80 millionN/AENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableNXTCNextCure9028.05 million23.03 millionOptionableODTOdonate Therapeutics14528.53 million14.58 millionNot OptionableSUPNSupernus Pharmaceuticals58055.99 million51.06 millionOptionableENTA, ODT, DERM, NXTC, and SUPN HeadlinesRecent News About These CompaniesHead-To-Head Analysis: Supernus Pharmaceuticals (NASDAQ:SUPN) & Personalis (NASDAQ:PSNL)July 5 at 2:41 AM | americanbankingnews.comMeritage Portfolio Management Acquires 10,622 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 4 at 5:47 AM | marketbeat.comSupernus Pharmaceuticals, Inc. (SUPN) - Yahoo FinanceJuly 3 at 4:16 PM | finance.yahoo.com8,151 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Robeco Institutional Asset Management B.V.July 3 at 4:02 AM | marketbeat.comSage Sacks Entire Staff After Supernus BuyoutJune 30, 2025 | biospace.comBSupernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJune 27, 2025 | msn.comSupernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five yearsJune 23, 2025 | uk.finance.yahoo.comSupernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Hold Rating by Wall Street ZenJune 21, 2025 | marketbeat.comSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJune 18, 2025 | businesswire.comSupernus Pharma to Buy Sage Therapeutics for Up to $795 MillionJune 16, 2025 | marketwatch.comSupernus enters depression drug market with up to $795 million Sage dealJune 16, 2025 | msn.comSupernus to acquire depression drugmaker SageJune 16, 2025 | msn.comSupernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage TherapeuticsJune 16, 2025 | msn.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.June 16, 2025 | prnewswire.comSupernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M DealJune 16, 2025 | gurufocus.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...June 16, 2025 | gurufocus.comSupernus Pharmaceuticals to Acquire Sage Therapeutics in a Strategic Move | SUPN stock newsJune 16, 2025 | gurufocus.comSage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.June 16, 2025 | barrons.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...June 16, 2025 | gurufocus.comSupernus Pharma to acquire Sage Therapeutics in up to $795 million dealJune 16, 2025 | reuters.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product PortfolioJune 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not Hype3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedSuper Micro Computer Stock's Rally Backed by Strong FinancialsBy Gabriel Osorio-Mazilli | June 19, 2025View Super Micro Computer Stock's Rally Backed by Strong FinancialsA Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesBy Gabriel Osorio-Mazilli | June 6, 2025View A Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesSnag These 3 Bargain Tech Stocks Before They PopBy Gabriel Osorio-Mazilli | June 27, 2025View Snag These 3 Bargain Tech Stocks Before They PopENTA, ODT, DERM, NXTC, and SUPN Company DescriptionsJourney Medical NASDAQ:DERM$7.10 +0.06 (+0.85%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Enanta Pharmaceuticals NASDAQ:ENTA$7.89 -0.08 (-1.00%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.NextCure NASDAQ:NXTC$0.44 +0.01 (+2.03%) As of 07/3/2025 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Odonate Therapeutics NASDAQ:ODTOdonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').Supernus Pharmaceuticals NASDAQ:SUPN$32.00 -0.08 (-0.23%) Closing price 07/3/2025 01:31 PM EasternExtended Trading$32.00 0.00 (0.00%) As of 07/3/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.